Latest Octagon Capital Advisors LP Stock Portfolio
$903Million– No. of Holdings #29
Octagon Capital Advisors LP Performance:
2026 Q1: 9.67%YTD: 9.67%2025: 104.18%
Performance for 2026 Q1 is 9.67%, and YTD is 9.67%, and 2025 is 104.18%.
About Octagon Capital Advisors LP and 13F Hedge Fund Stock Holdings
On 2026-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, Octagon Capital Advisors LP reported an equity portfolio of $903.6 Millions as of 31 Mar, 2026.
The top stock holdings of Octagon Capital Advisors LP are , COGT, . The fund has invested 18.1% of it's portfolio in DIANTHUS THERAPEUTICS INC and 10% of portfolio in COGENT BIOSCIENCES INC.
The fund managers got completely rid off MIND MEDICINE MINDMED INC (MNMD), CIDARA THERAPEUTICS INC (CDTX) and RAPT THERAPEUTICS INC (RAPT) stocks. They significantly reduced their stock positions in PHARVARIS N V (PHVS), EVOMMUNE INC and TREVI THERAPEUTICS INC (TRVI). Octagon Capital Advisors LP opened new stock positions in DEFINIUM THERAPEUTICS INC, MIRUM PHARMACEUTICALS INC (MIRM) and XENON PHARMACEUTICALS INC (XENE). The fund showed a lot of confidence in some stocks as they added substantially to OCULAR THERAPEUTIX INC (OCUL), PRECISION BIOSCIENCES INC (DTIL) and KALVISTA PHARMACEUTICALS INC (KALV).
The top stock holdings of Octagon Capital Advisors LP are , COGT, . The fund has invested 18.1% of it's portfolio in DIANTHUS THERAPEUTICS INC and 10% of portfolio in COGENT BIOSCIENCES INC.
The fund managers got completely rid off MIND MEDICINE MINDMED INC (MNMD), CIDARA THERAPEUTICS INC (CDTX) and RAPT THERAPEUTICS INC (RAPT) stocks. They significantly reduced their stock positions in PHARVARIS N V (PHVS), EVOMMUNE INC and TREVI THERAPEUTICS INC (TRVI). Octagon Capital Advisors LP opened new stock positions in DEFINIUM THERAPEUTICS INC, MIRUM PHARMACEUTICALS INC (MIRM) and XENON PHARMACEUTICALS INC (XENE). The fund showed a lot of confidence in some stocks as they added substantially to OCULAR THERAPEUTIX INC (OCUL), PRECISION BIOSCIENCES INC (DTIL) and KALVISTA PHARMACEUTICALS INC (KALV).
Octagon Capital Advisors LP Equity Portfolio Value
Last Reported on: 15 May, 2026
Octagon Capital Advisors LP Annual Return Estimates Vs S&P 500
Our best estimate is that Octagon Capital Advisors LP made a return of 9.67% in the last quarter. In trailing 12 months, it's portfolio return was 165.91%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| definium therapeutics inc | 46,116,000 |
| mirum pharmaceuticals inc | 31,307,600 |
| xenon pharmaceuticals inc | 28,493,500 |
| terns pharmaceuticals inc | 27,941,600 |
| disc medicine inc | 17,263,800 |
| aktis oncology inc | 17,189,600 |
| context therapeutics inc | 13,755,000 |
| perspective therapeutics inc | 3,300,780 |
New stocks bought by Octagon Capital Advisors LP
Additions
| Ticker | % Inc. |
|---|---|
| ocular therapeutix inc | 20.7 |
| precision biosciences inc | 16.62 |
| kalvista pharmaceuticals inc | 13.87 |
| alumis inc | 11.85 |
| bioage labs inc | 9.39 |
| palisade bio inc | 7.4 |
Additions to existing portfolio by Octagon Capital Advisors LP
Reductions
| Ticker | % Reduced |
|---|---|
| pharvaris n v | -75.43 |
| evommune inc | -71.31 |
| trevi therapeutics inc | -47.25 |
| gossamer bio inc | -44.31 |
| lexeo therapeutics inc | -36.23 |
| bridgebio oncology therapeut | -31.07 |
| kymera therapeutics inc | -20.56 |
| dianthus therapeutics inc | -19.45 |
Octagon Capital Advisors LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| mind medicine mindmed inc | -29,859,700 |
| corbus pharmaceuticals hldgs | -7,773,700 |
| pepgen inc | -4,557,000 |
| rapt therapeutics inc | -19,441,400 |
| cidara therapeutics inc | -22,089,000 |
Octagon Capital Advisors LP got rid off the above stocks
Sector Distribution
Octagon Capital Advisors LP has about 53.3% of it's holdings in Others sector.
- Others
- Healthcare
| Sector | % |
|---|---|
| Others | 53.3 |
| Healthcare | 46.7 |
Market Cap. Distribution
Octagon Capital Advisors LP has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
- UNALLOCATED
- MID-CAP
- SMALL-CAP
- MICRO-CAP
| Category | % |
|---|---|
| UNALLOCATED | 53.3 |
| MID-CAP | 28.3 |
| SMALL-CAP | 12.8 |
| MICRO-CAP | 5.6 |
Stocks belong to which Index?
About 28.6% of the stocks held by Octagon Capital Advisors LP either belong to S&P 500 or RUSSELL 2000 index.
- Others
- RUSSELL 2000
| Index | % |
|---|---|
| Others | 71.4 |
| RUSSELL 2000 | 28.6 |
Octagon Capital Advisors LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Octagon Capital Advisors LP
Octagon Capital Advisors LP has 29 stocks in it's portfolio. About 68.6% of the portfolio is in top 10 stocks. GOSS proved to be the most loss making stock for the portfolio. was the most profitable stock for Octagon Capital Advisors LP last quarter.
Last Reported on: 15 May, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| CDTX | cidara therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CNTA | centessa pharmaceuticals plc | 3.30 | 750,000 | 29,790,000 | unchanged | 0.00 | ||
| CNTX | context therapeutics inc | 1.52 | 5,250,000 | 13,755,000 | new | |||
| COGT | cogent biosciences inc | 10.01 | 2,350,000 | 90,451,500 | unchanged | 0.00 | ||
| CRBP | corbus pharmaceuticals hldgs | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| DBVT | dbv technologies s a | 1.33 | 574,200 | 11,995,000 | unchanged | 0.00 | ||
| DTIL | precision biosciences inc | 1.36 | 2,236,730 | 12,302,000 | added | 16.62 | ||
| GOSS | gossamer bio inc | 0.28 | 7,750,000 | 2,545,880 | reduced | -44.31 | ||
| KALV | kalvista pharmaceuticals inc | 3.23 | 1,450,000 | 29,188,500 | added | 13.87 | ||
| KYMR | kymera therapeutics inc | 3.92 | 425,000 | 35,398,200 | reduced | -20.56 | ||
| MIRM | mirum pharmaceuticals inc | 3.46 | 338,900 | 31,307,600 | new | |||
| MNMD | mind medicine mindmed inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| OCUL | ocular therapeutix inc | 2.97 | 3,166,600 | 26,821,100 | added | 20.7 | ||
| PALI | palisade bio inc | 1.99 | 10,276,300 | 17,983,600 | added | 7.4 | ||
| PEPG | pepgen inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| PHVS | pharvaris n v | 0.52 | 165,000 | 4,661,250 | reduced | -75.43 | ||
| RAPT | rapt therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| TERN | terns pharmaceuticals inc | 3.09 | 530,000 | 27,941,600 | new | |||
| TRVI | trevi therapeutics inc | 1.96 | 1,485,000 | 17,716,000 | reduced | -47.25 | ||
| TSHA | taysha gene therapies inc | 4.38 | 8,859,910 | 39,603,800 | unchanged | 0.00 | ||